Matinas BioPharma Holdings (MTNB) EBITDA Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) reported EBITDA Margin of 829.26% for Q2 2023, down 26031.0% year-over-year from N/an in Q2 2022, and up 41.15% quarter-over-quarter from 1409.07% in Q1 2023.
Matinas BioPharma Holdings (MTNB) EBITDA Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 8 years of EBITDA Margin data on file, last reported at 829.26% in Q2 2023.
- EBITDA Margin for Q2 2023 came in at 829.26%, down 26031.0% year-over-year; the trailing twelve-month figure through Dec 2023 was 2038.23% (down 135845.0% YoY), and the FY2023 annual result was 2038.23%, down 135831.0% from the prior year.
- EBITDA Margin grew to 829.26% in Q2 2023 per MTNB's latest filing, from 1409.07% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2055032.73% in Q4 2021 and troughed at 15144.41% in Q1 2021.
- A 5-year average of 203699.61% and a median of 699.11% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin jumped 204472564 bps in 2021, then slumped 205536415 bps in 2022.
- A 5-year view of EBITDA Margin shows it stood at 3724.14% in 2019, then jumped by 377 bps to 10307.09% in 2020, then surged by 19838 bps to 2055032.73% in 2021, then slumped by 100 bps to 331.42% in 2022, then plunged by 150 bps to 829.26% in 2023.
- Business Quant data shows MTNB's EBITDA Margin at 829.26% in Q2 2023, 1409.07% in Q1 2023, and 331.42% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -829.26% |
| Mar 31, 2023 | -1,409.07% |
| Dec 31, 2022 | -331.42% |
| Sep 30, 2022 | -530.86% |
| Jun 30, 2022 | -568.96% |
| Dec 31, 2021 | 2,055,032.73% |
| Mar 31, 2021 | -15,144.41% |
| Dec 31, 2020 | 10,307.09% |
| Sep 30, 2020 | -5,805.59% |
| Jun 30, 2019 | -3,724.14% |
| Jun 30, 2018 | -3,791.13% |
| Mar 31, 2018 | -13,764.74% |
| Dec 31, 2017 | -10,311.72% |
| Sep 30, 2017 | -7,589.85% |
| Jun 30, 2017 | -8,854.73% |
| Mar 31, 2017 | -29,976.78% |
| Sep 30, 2015 | -3,606.48% |
| Jun 30, 2015 | -3,119.21% |
| Mar 31, 2015 | -4,456.62% |